ABSTRACT: The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue. A group of 60 patients with PSD were assigned to receive duloxetine, citalopram, or sertraline and were assessed over a 3-month period for depression, anxiety, and fatigue. Improvement of depression and anxiety, but not fatigue, was observed in all study groups. Duloxetine was well tolerated and significantly more effective than citalopram and sertraline for the treatment of anxiety symptoms in PSD patients. None of the antidepressants used was effective for reducing symptoms of fatigue.
The Journal of neuropsychiatry and clinical neurosciences 06/2012; 24(3):349-53. · 2.34 Impact Factor
JAMA The Journal of the American Medical Association 05/2009; 301(13):1338-9; author reply 1339. · 30.03 Impact Factor
Annals of General Psychiatry. 01/2008;
ABSTRACT: The need for sensitive biological markers to detect and prove recent drinking has been the focus of many research groups. The aim of our study was to investigate the alterations of biological markers in a population of alcohol dependent individuals during the detoxification period.
Fifty-two alcohol-dependent individuals were admitted for alcohol detoxification on an inpatient basis. Carbohydrate-deficient transferrin (CDT), gamma-glutamyl transpeptidase (gamma-GT), interleukin-6 (IL-6), mean corpuscular volume (MCV), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) were obtained at admission and on a 15-day basis. Comparisons between measures were made with t-test.
All biochemical parameters associated with alcoholism, with the exception of MCV, were statistically significantly decreased during the detoxification process (p<0.05).
CDT is an excellent marker of alcohol overconsumption during evaluation, as well as during the detoxification treatment. IL-6 could serve as an additional marker to CDT, a point needing further investigation.
In vivo (Athens, Greece) 24(3):325-8. · 1.17 Impact Factor